Answers are grounded in this paper and cite their sources.
Analysis reveals risks of severe GI toxicity with cabozantinib in advanced hepatocellular carcinoma, suggesting personalized treatment approaches.
Cabozantinib carries a disproportionately higher risk of severe GI toxicity compared with regorafenib. Clinicians should consider prophylactic anti-diarrhoeal therapy, routine liver-function monitoring, and early dose modifications when initiating cabozantinib, especially in male patients aged 45-64 years. These data supported personalized second-line TKI selection after first-line failure.
No takes yet. Share an insight, caveat, or question.
Sui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: